Cargando…

Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients

OBJECTIVE: Limited evidence is available on predictors of medical resource utilization (MRU) and related direct costs, especially in treatment-experienced patients infected with genotype 1 hepatitis C virus (HCV). This study aimed at investigating patient and treatment characteristics that predict M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akpo, Essè Ifèbi Hervé, Sbarigia, Urbano, Wan, George, Kleintjens, Joris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662942/ https://www.ncbi.nlm.nih.gov/pubmed/26416653 http://dx.doi.org/10.1007/s40268-015-0109-5

Ejemplares similares

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy
por: Akpo, Essè Ifèbi Hervé, et al.
Publicado: (2015)

Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom
por: Akpo, Esse Ifebi Herve, et al.
Publicado: (2020)

Burden of Pertussis in Adults Aged 50 Years and Older: A Retrospective Database Study in England
por: Harrington, Lauriane, et al.
Publicado: (2023)

1481. Incidence of Pertussis in Older Adults in England and the United Kingdom: A Large, Retrospective Database Analysis
por: Aris, Emmanuel, et al.
Publicado: (2020)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

Conceptual framework for outcomes research studies of hepatitis C: an analytical review
por: Sbarigia, Urbano, et al.
Publicado: (2016)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Preferences of Patients with Chronic Hepatitis B – A Discrete Choice Experiment on the Acceptability of Functional Cure
por: Hardtstock, Fraence, et al.
Publicado: (2020)

Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
por: Wigfield, Peter, et al.
Publicado: (2019)

Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population
por: Sbarigia, Urbano, et al.
Publicado: (2020)

Impact of Stigma on People Living with Chronic Hepatitis B
por: Smith-Palmer, Jayne, et al.
Publicado: (2020)

A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
por: Nieland, Kaspar, et al.
Publicado: (2021)

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
por: Polilli, Ennio, et al.
Publicado: (2016)

The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam
por: Nguyen, Huyen Anh, et al.
Publicado: (2020)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

The Estimation of Direct Medical Costs of Treating Patients With Chronic Hepatitis B and C in Iran
por: Kalantari, Hamid, et al.
Publicado: (2012)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
por: Kleintjens, Joris, et al.
Publicado: (2013)

Characteristics, determinants and perspectives of experienced medical humanitarians: a qualitative approach
por: Asgary, Ramin, et al.
Publicado: (2014)

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
por: Vandekerckhove, Linos, et al.
Publicado: (2011)

Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea
por: Kim, Do Young, et al.
Publicado: (2016)

Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy
por: Kim, Do Young
Publicado: (2017)

Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
por: Yun, Haoya, et al.
Publicado: (2020)

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
por: Yang, Chi-Chieh, et al.
Publicado: (2015)

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1
por: Linas, Benjamin P., et al.
Publicado: (2016)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
por: Lee, Hyun Woong, et al.
Publicado: (2017)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
por: Tasavon Gholamhoseini, Mohammad, et al.
Publicado: (2022)

Sociodemographic Determinants of Nonadherence to Depression and Anxiety Medication among Individuals Experiencing Homelessness
por: Eshtehardi, Sahar S., et al.
Publicado: (2021)

Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2014)

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
por: Gane, Edward J., et al.
Publicado: (2017)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan
por: Huang, Ying-Chou, et al.
Publicado: (2021)

Comparison of Childbirth Delivery Outcomes and Costs of Care Between Women Experiencing vs Not Experiencing Homelessness
por: Yamamoto, Ayae, et al.
Publicado: (2021)

Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype‐specific PCR and deep sequencing
por: McNaughton, A. L., et al.
Publicado: (2018)

Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study
por: Azahar, Siti Norain, et al.
Publicado: (2022)

Economic study of the value of expanding HCV treatment capacity in Germany
por: Sbarigia, Urbano, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus
por: Fawsitt, Christopher G., et al.
Publicado: (2019)

Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
por: Yuen, Man-Fung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vud8i4f4l368gt4d5f1mv3u6no